Geographic Atrophy

Whitecap is currently developing 2 therapies for potential use in glaucoma and geographic atrophy.

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.

The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration (FDA) and Astellas.

The financing will go toward its ongoing phase 2b/3 and planned pivotal phase 3 clinical trial for AVD-104.

The potential gene therapy candidate is being evaluated for geographic atrophy.

The trial is evaluating GAL-101 eye drops in patients with geographic atrophy, an advanced form of dry AMD.

This year was brimming with advancements in eye care.

A global survey explores the impact of geographic atrophy (GA) on quality of life, revealing similar challenges for individuals with unilateral and bilateral GA. Researchers also highlight the need for improved education, support, and treatment options.

Tenpoint Therapeutics and Visus Therapeutics have merged to focus on aging-related ocular conditions, with key products including BRIMOCHOL PF for presbyopia and therapies for cataracts and geographic atrophy.

A look at the latest advances from flash photography to AI-driven OCT

The annual meeting brought announcements and insights from companies in the retina care space.

The organization will provide resources for spreading awareness and educating patients and care givers.

Prevent Blindness announces its fourth annual Geographic Atrophy Awareness Week, December 2 to 8, 2024. The organization offers free educational resources, including videos and guides, and supports GA patients through programs like Living Well With Low Vision.

Patients treated with investigational oral therapy gildeuretinol (ALK-001) showed a statistically significant reduction in the GA lesion growth rate.

Astellas said in a press release that the FDA comments in the CRL relate to proposed labeling language, not safety.

The FDA comments in the CRL relate to proposed labelling language, not safety, Astellas said in a press release.

Key findings include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating significant potential for the treatment option.

In a recent Modern Retina case-based discussion, Ferhina S. Ali, MD, MPH, discussed how to effectively manage geographic atrophy (GA).

This merger creates an innovative biotechnology company with a broader focus in the advancement of multiple disease therapies.

Srinivas R. Sadda, MD, described the advantages and disadvantages of the various imaging technologies used to evaluate GA at the AAO 2024 conference.

PST-611 is a first in class non-viral vectorized therapy for the treatment of dry AMD/GA coding for human transferrin.

OCT-based AI analysis brings changes in GA and therapeutic responses into sharp focus.

The European Association for Vision and Eye Research 27th EVER Congress will be held in Valencia, Spain, November 3 – 5, 2024.

The investigators undertook a study in which they retrospectively evaluated the presence and amount of small HRF in the eyes of patients with different macular atrophic phenotypes.

David Eichenbaum, MD, spoke with Modern Retina to provide and overview on his presentation at ASRS 2024 and the current state of geographic atrophy treatment.